Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) EBIT: €501 Mil (TTM As of Mar. 2026)


FRA:GU5 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
72 GF Score
Price €1.57
GF Value €2.33
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co EBIT?

Guangzhou Baiyunshan Pharmaceutical Holdings Co FRA:GU5 -2.48% 72 EBIT is €501 Mil as of Mar. 2026. GuruFocus rates FRA:GU5 with a GF Score™ of 72/100 and a GF Value™ of €2.33 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €290 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €501 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Guangzhou Baiyunshan Pharmaceutical Holdings Co's annualized ROC % for the quarter that ended in Mar. 2026 was 15.59%. Guangzhou Baiyunshan Pharmaceutical Holdings Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 38.49%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Guangzhou Baiyunshan Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 9.74%.

Guangzhou Baiyunshan Pharmaceutical Holdings Co  (FRA:GU5) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1134.688 * ( 1 - 17.39% )/( (5541.825 + 6482.868)/ 2 )
=937.3657568/6012.3465
=15.59 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10247.12 - 2893.298 - ( 1811.997 - max(0, 4743.938 - 7459.197+1811.997))
=5541.825

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11265.153 - 3234.597 - ( 1547.688 - max(0, 5116.051 - 8166.076+1547.688))
=6482.868

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Guangzhou Baiyunshan Pharmaceutical Holdings Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1160.252/( ( (1014.168 + max(1690.581, 0)) + (1059.002 + max(2265.342, 0)) )/ 2 )
=1160.252/( ( 2704.749 + 3324.344 )/ 2 )
=1160.252/3014.5465
=38.49 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2043.024 + 1593.035 + 1371.322) - (2893.298 + 0 + 423.502)
=1690.581

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2496.996 + 1564.907 + 1660.048) - (3234.597 + 0 + 222.012)
=2265.342

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Guangzhou Baiyunshan Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=500.868/5143.870
=9.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co EBIT Related Terms

Guangzhou Baiyunshan Pharmaceutical Holdings Co EBIT Historical Data

* Premium members only.

The historical data trend for Guangzhou Baiyunshan Pharmaceutical Holdings Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co EBIT Chart

Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 714.32 741.70 713.63 528.05 496.09

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 297.64 116.14 143.00 -48.33 290.06

FRA:GU5 vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-EBIT falls into.


FRA:GU5
72GF Score
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €501 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €501 Mil mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a EBIT of €501 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's EBIT too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EBIT is €501 Mil. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's EBIT compare to MCK and COR?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's EBIT of €501 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EBIT is €501 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.33, compared to a current price of €1.57 — trading 32.6% below its estimated fair value. The current EBIT is €501 Mil. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current EBIT is €501 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of €1.57 is trading 32.6% below its estimated GF Value™ of €2.33. GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.

Key valuation signals for FRA:GU5:

  • EBIT: €501 Mil
  • GF Value™: €2.33 vs. price of €1.57 (32.6% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description

Other Exchanges 00874:Hong Kong600332:China
Address 45 Sha Mian North Street, Liwan District, Guangdong Province, Guangzhou, CHN, 510130
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
72GF Score

Get the complete analysis for FRA:GU5

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.57
Price
€2.33
GF Value